Modern view on the treatment of onychomycosis


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The literature review is devoted to the etiology, epidemiology and modern possibilities of treatment of onychomycosis. Information on the use of external and systemic products, as well as new techniques - laser and photodynamic therapy - is presented.

Full Text

Restricted Access

About the authors

V. Yu Vasenova

FSBEI HE RNSMU n.a. N.I. Pirogov of RMPH

Email: vasenova@mail.ru
MD, Professor at the Department of Skin Diseases and Cosmetology FAPE

Yu. S Butov

FSBEI HE RNSMU n.a. N.I. Pirogov of RMPH

Department of Skin Diseases and Cosmetology FAPE

References

  1. Kushwaha A., Murthy R.N., Murthy S.N., Elkeeb R., Hui X., Maibach H.I. Emerging therapies for the treatment of ungual onychomycosis. Drug Dev Ind Pharm. 2015;41(10):1575-81.
  2. Papini M., Piraccini B.M., Difonzo E., Brunoro A. Epidemiology of onychomycosis in Italy: prevalence data and risk factor identification. Mycoses. 2015;58(11):659-64.
  3. Ayanlowo O., Oladele R.O. Onychomycosis: updates and management challenges. A review. Niger. Postgrad. Med. J. 2014;21(2):185-91.
  4. Rosen T., Friedlander S.F., Kircik L., Zirwas M.J., Stein Gold L., Bhatia N., Gupta A.K. Onychomycosis: epidemiology, diagnosis, and treatment in a changing landscape. J. Drugs Dermatol. 2015;14(3):223-33.
  5. Polat M., Ilan M.N. Dermatological Complaints of the Elderly Attending a Dermatology Outpatient Clinic in Turkey: A Prospective Study over a One-year Period. Acta Dermatovenerol. Croat. 2015;23(4):277-81.
  6. Yadav P., Singal A., Pandhi D., Das S. Clinico-mycological study of dermatophyte toenail onychomycosis in new delhi, India. Indian. J. Dermatol. 2015;60(2):153-58.
  7. Ribeiro C.S., Zaitz C., Framil V.M., Ottoboni T.S., Tonoli M.S., Ribeiro R.P. Descriptive study of onychomycosis in a hospital in Sao Paulo. Braz. J. Microbiol. 2015;46(2):485-92.
  8. Сергеев А.Ю. Грибковые заболевания ногтей. М., 2001. 155 с.
  9. Сергеев Ю.В., Сергеев А.Ю. Проект «Горячая линия»: итоги и результаты. Успехи медицинской микологии. 2003;2:153-54.
  10. Onalan O., Adar A., Keles H., Ertugrul G., Ozkan N., Aktas H., Karakaya E. Onychomycosis is associated with subclinical atherosclerosis in patients with diabetes. Vasa. 2015;44(1):59-64.
  11. Gupta A.K., Nakrieko K.A. Trichophyton rubrum DNA strain switching increases in patients with onychomycosis failing antifungal treatments. Br. J. Dermatol. 2015;172(1):74-80.
  12. Otasevic S., Barac A., Pekmezovic M., Tasic S., Ignjatovic A., Momcilovic S., Stojanovic P., Arsic Arsenijevic V., Hay R. The prevalence of Candida onychomycosis in Southeastern Serbia from 2011 to 2015. Mycoses. 2016;59(3):167-72.
  13. Afshar P., Khodavaisy S., Kalhori S., Ghasemi M., Razavyoon T. Onychomycosis in north-East of Iran. Iran. J. Microbiol. 2014;6(2):98-103.
  14. Lemus-Espinoza D., Maniscalchi T.M., Villarroel O, Bonoli S.B., Wahab F., Garcia O. Superficial mycoses in patients from Anzoategui state, Venezuela, period 2002-2012. Invest. Clin. 2014;55(4):311-20.
  15. Sotirion E., Konssidon-Eremondi Th., Kastoridon Ch., et al. Erysipelas and tinea pedis: a 4 years review. JEADV. 2004;18 (2):385.
  16. Lipner S.R., Scher R.K. Onychomycosis - A Small Step for Quality of Care. Curr. Med. Res.Opin. 2016;1-10.
  17. Claveau J., Vender R.B., Gupta A.K. Multitherapy approach to onychomycosis therapy. J. Cutan. Med. Surg. 2006;10(Suppl. 2):44-7.
  18. Piraccini B.M., Bruni F., Alessandrini A., Starace M. Evaluation of efficacy and tolerability of 4 weeks Bifonazole treatment after nail ablation with 40% urea in mild to moderate distal subugnual onychomycosis. G. Ital. Dermatol. Venereol. 2015. [Epub ahead of print].
  19. Ghannoum M., Sevin K., Sarkany M. Amorolfine 5% Nail Lacquer Exhibits Potent Antifungal Activity Compared to Three Acid-Based Devices Indicated for the Treatment of Onychomycosis: An In Vitro Nail Penetration Assay. Dermatol Ther (Heidelb). 2016. [Epub ahead of print].
  20. Сонин Д.Б., Тарасова М.А., Борискина Л.А., Буданцева М.В. Опыт применения препаратов аморолфина в терапии онихомикоза. Consilium Medicum. Дерматология (Прил.). 2015;1:42-6.
  21. Bunyaratavej S., Leeyaphan C., Rujitharanawong C., Surawan T.M., Muanprasat C., Matthapan L. Efficacy of 5% amorolfine nail lacquer in Neoscytalidium dimidiatum onychomycosis. J. Dermatolog. Treat. 2015;11:1-5.
  22. Sigurgeirsson B., Olafsson J.H., Steinsson J.T., etal. Efficacy of amorolfine nail lacquer for the prophylaxis of onychomycosis over 3 years. J. Eur. Acad. Dermatol. Venereol. 2010;24(8):910-15.
  23. Белоусова Т.А., Горячкина М.В. Современный взгляд на проблему онихомикоза. Фарматека. 2010;11(205):32-7.
  24. Gupta A.K, Simpson F.C., Heller D.F. The future of lasers in onychomycosis. J. Dermatolog. Treat. 201;27(2):167-72.
  25. de Oliveira G.B., Antonio J.R., Antonio C.R., Tom F.A. The association of fractional CO2 laser 10.600nm and photodynamic therapy in the treatment of onychomycosis. An. Bras. Dermatol. 2015;90(4):468-71.
  26. Wanitphakdeedecha R., Thanomkitti K., Bunyaratavej S., Manuskiatti W. Efficacy and safety of 1064-nm Nd:YAG laser in treatment of onychomycosis. J. Dermatolog. Treat. 2016;27(1):75-9.
  27. Helou J., Maatouk I., Hajjar M.A., Moutran R. Evaluation of Nd:YAG laser device efficacy on onychomycosis: a case series of 30 patients. Mycoses. 2016;59(1):7-11.
  28. Carney C., Cantrell W., Warner J., Elewski B. Treatment of onychomycosis using a submillisecond 1064-nm neodymium:yttrium-alu-minum-garnet laser. J. Am. Acad. Dermatol. 2013;69(4):578-82.
  29. Bhuptani R.S., Deshpande K.M., Patravale V.B. Transungual permeation: current insights. Drug Deliv Transl Res. 2015 Sep 29. [Epub ahead of print].
  30. Robres P., Aspiroz C., Rezusta A., Gilaberte Y. Usefulness of Photodynamic Therapy in the Management of Onychomycosis. Actas Dermosifiliogr. 2015;106(10):795-805.
  31. Claveau J., Vender R.B., Gupta A.K. Multitherapy approach to onychomycosis therapy. J. Cutan. Med. Surg. 2006;10(Suppl. 2):44-7.
  32. Gupta A.K., Poulin Y., Lynde C.W. Canadian perspectives on antifungal treatment for onychomycosis. J. Cutan. Med. Surg. 2006;10(Suppl. 2):34-8.
  33. Poulin Y., Thomas R., Gupta A.K. Brief treatment guide for onychomycosis. J. Cutan. Med. Surg. 2006;10(Suppl. 2):39-43.
  34. Finch J.J., Warshaw E.M. Toenail onychomycosis: current and future treatment options. Dermatol. Ther. 2007;20(1):31-46.
  35. de Sa D.C., Lamas A.P., Tosti A. Oral therapy for onychomycosis: an evidence-based review. Am. J. Clin. Dermatol. 2014;15(1):17-36.
  36. Gupta A.K., Ryder J.E., Lynch L.E., Tavakkol A. The use of terbinafine in the treatment of onychomycosis in adults and special populations: a review of the evidence. J. Drugs Dermatol. 2005;4(3):302-
  37. Baran R., Sigurgeirsson B., de Berker D., Kaufmann R., Lecha M., Faergemann J., Kerrouche N., Sidou F. A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement. Br. J. Dermatol. 2007;157(1):149-57.
  38. Wen J., Lin Z.F. Effect of terbinafine in treating onychomycosis in children: clinical observation of 88 cases. Di Yi Jun Yi Da Xue Xue Bao, 2005;25(5):582-83.
  39. Takiuchi.I, Morishita N., Hamaguchi T., Ninomiya J., Higuchi R. Treatment Outcome and Relapse with Short-term Oral Terbinafine (250 mg/day) in Tinea Pedis. Nippon Ishinkin Gakkai Zasshi. 2005;46(4):285-89.
  40. Gupta A.K., Cooper E.A., Paquet M. Recurrences of dermatophyte toenail onychomycosis during long-term follow-up after successful treatments with mono- and combined therapy of terbinafine and itraconazole. J. Cutan. Med. Surg. 2013;17(3):201-6.
  41. Рукавишникова В.М. Микозы стоп. М., 200 c.
  42. Kawada A., Aragane Y., Tezuka T. Clinical and pharmacokinetic studies of continuous itraconazole for the treatment of onychomycosis. J. Dermatol. 2004;31(2):104-8.
  43. Maleszka R., Adamski Z. The treatment of extensive onychomycosis in aged patients. Wiad Parazytol. 2001;47(4):817-22.
  44. Maddin S., Quiring J., Bulger L. Randomized, placebo-controlled, phase 3 study of itraconazole for the treatment of onychomycosis. J. Drugs Dermatol. 2013;12(7):758-63.
  45. Pajaziti L., Vasili E. Treatment of Onychomycosis -a Clinical Study. Med Arch. 2015;69(3):173- 76.
  46. Westerberg D.P., Voyack M.J. Onychomycosis: Current trends in diagnosis and treatment. Am. Fam. Physician. 2013;88(11): 762-70.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies